Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Neurochem Int. 2017 Feb 8;105:21–31. doi: 10.1016/j.neuint.2017.02.003

Figure 6. Forskolin, but neither haloperidol metabolites nor the S1R reference agonist 4-PPBP, increase steady state BDNF mRNA levels as determined by qPCR.

Figure 6

CCF-STTG1 cells were treated with vehicle, IBMX, forskolin + IBMX, haloperidol metabolite I and II, and 4-PPBP for 3 hours. Three hours was selected because a time course study revealed that 3 hrs stimulation resulted in the maximum response for forskolin. Forskolin was used as a positive control because it was previously shown to increase BDNF mRNA levels (He et al., 2010). IBMX was utilized to prevent cAMP degradation and as expected, it had no effect on BDNF mRNA levels in the absence of forskolin. Haloperidol metabolite I and II and 4-PPBP also had no effect on BDNF mRNA levels. Only forskolin was able to induce a > 3 fold increase in BDNF mRNA levels. Statistical significance at P < 0.05 was determined by ANOVA followed by Bonferroni post-hoc test. * Different from vehicle (DMSO).